OBJECTIVE: To determine the impact of tuberculosis (TB) treatment at the time of combination antiretroviral therapy (cART) initiation on virologic and CD4 cell count response to cART. METHODS: Systematic review and meta-analysis of studies reporting HIV RNA and CD4 cell count response, stratified by TB treatment status at cART initiation. Stratified random-effects and meta-regression analyses were used when possible. RESULTS: Twenty-five eligible cohort studies reported data on 49 578 (range 42-15 646) adults, of whom 8826 (18%) were receiving TB treatment at cART initiation. Seventeen studies reported virologic response; 21 reported CD4 cell count response. The summarized random-effects relative risk (RRRE) of virologic suppression in those receiving vs. not receiving TB treatment at different time points following cART initiation was 1.06 (0.86-1.29) at 1-4 months, 0.91 (0.83-1.00) at 6 months, 0.99 (0.94-1.05) at 11-12 months, and 0.99 (0.77-1.28) at 18-48 months. The overall RRRE at 1-48 months was 0.97 (95% confidence interval 0.92-1.03). Available data regarding the effect of TB treatment on virologic failure were heterogeneous and inconclusive (13 estimates). Differences in median CD4 cell count gain between those receiving vs. not receiving TB treatment ranged from -10 to 60 cells/μl (median 27) by 6 months (seven estimates) and -10 to 29 (median 6) by 11-12 months (five estimates), although the heterogeneity of the response measures did not support meta-analysis. CONCLUSION: Patients receiving TB treatment at cART initiation experience similar virologic suppression and CD4 cell count reconstitution as those not receiving TB treatment, reinforcing the need to start cART during TB treatment and allowing more confidence in clinical decision-making.
OBJECTIVE: To determine the impact of tuberculosis (TB) treatment at the time of combination antiretroviral therapy (cART) initiation on virologic and CD4 cell count response to cART. METHODS: Systematic review and meta-analysis of studies reporting HIV RNA and CD4 cell count response, stratified by TB treatment status at cART initiation. Stratified random-effects and meta-regression analyses were used when possible. RESULTS: Twenty-five eligible cohort studies reported data on 49 578 (range 42-15 646) adults, of whom 8826 (18%) were receiving TB treatment at cART initiation. Seventeen studies reported virologic response; 21 reported CD4 cell count response. The summarized random-effects relative risk (RRRE) of virologic suppression in those receiving vs. not receiving TB treatment at different time points following cART initiation was 1.06 (0.86-1.29) at 1-4 months, 0.91 (0.83-1.00) at 6 months, 0.99 (0.94-1.05) at 11-12 months, and 0.99 (0.77-1.28) at 18-48 months. The overall RRRE at 1-48 months was 0.97 (95% confidence interval 0.92-1.03). Available data regarding the effect of TB treatment on virologic failure were heterogeneous and inconclusive (13 estimates). Differences in median CD4 cell count gain between those receiving vs. not receiving TB treatment ranged from -10 to 60 cells/μl (median 27) by 6 months (seven estimates) and -10 to 29 (median 6) by 11-12 months (five estimates), although the heterogeneity of the response measures did not support meta-analysis. CONCLUSION:Patients receiving TB treatment at cART initiation experience similar virologic suppression and CD4 cell count reconstitution as those not receiving TB treatment, reinforcing the need to start cART during TB treatment and allowing more confidence in clinical decision-making.
Authors: Dirk Bassler; Matthias Briel; Victor M Montori; Melanie Lane; Paul Glasziou; Qi Zhou; Diane Heels-Ansdell; Stephen D Walter; Gordon H Guyatt; David N Flynn; Mohamed B Elamin; Mohammad Hassan Murad; Nisrin O Abu Elnour; Julianna F Lampropulos; Amit Sood; Rebecca J Mullan; Patricia J Erwin; Clare R Bankhead; Rafael Perera; Carolina Ruiz Culebro; John J You; Sohail M Mulla; Jagdeep Kaur; Kara A Nerenberg; Holger Schünemann; Deborah J Cook; Kristina Lutz; Christine M Ribic; Noah Vale; German Malaga; Elie A Akl; Ignacio Ferreira-Gonzalez; Pablo Alonso-Coello; Gerard Urrutia; Regina Kunz; Heiner C Bucher; Alain J Nordmann; Heike Raatz; Suzana Alves da Silva; Fabio Tuche; Brigitte Strahm; Benjamin Djulbegovic; Neill K J Adhikari; Edward J Mills; Femida Gwadry-Sridhar; Haresh Kirpalani; Heloisa P Soares; Paul J Karanicolas; Karen E A Burns; Per Olav Vandvik; Fernando Coto-Yglesias; Pedro Paulo M Chrispim; Tim Ramsay Journal: JAMA Date: 2010-03-24 Impact factor: 56.272
Authors: Andrew Boulle; Gilles Van Cutsem; Katherine Hilderbrand; Carol Cragg; Musaed Abrahams; Shaheed Mathee; Nathan Ford; Louise Knight; Meg Osler; Jonny Myers; Eric Goemaere; David Coetzee; Gary Maartens Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Daniel Westreich; Patrick MacPhail; Annelies Van Rie; Babatyi Malope-Kgokong; Prudence Ive; Dennis Rubel; Ronan Boulmé; Joseph Eron; Ian Sanne Journal: AIDS Date: 2009-03-27 Impact factor: 4.177
Authors: Cristina Mussini; Christian Manzardo; Margaret Johnson; Antonella d'Arminio Monforte; Caterina Uberti-Foppa; Andrea Antinori; M John Gill; Laura Sighinolfi; Vanni Borghi; Adriano Lazzarin; José M Miró; Caroline Sabin Journal: AIDS Date: 2008-11-30 Impact factor: 4.177
Authors: Abraham M Siika; Constantin T Yiannoutsos; Kara K Wools-Kaloustian; Beverly S Musick; Ann W Mwangi; Lameck O Diero; Sylvester N Kimaiyo; William M Tierney; Jane E Carter Journal: PLoS One Date: 2013-01-02 Impact factor: 3.240
Authors: Viviane D Lima; Mark Hull; David McVea; William Chau; P Richard Harrigan; Julio Sg Montaner Journal: J Int AIDS Soc Date: 2016-08-05 Impact factor: 5.396
Authors: Anton Reepalu; Taye Tolera Balcha; Erik Sturegård; Patrik Medstrand; Per Björkman Journal: Open Forum Infect Dis Date: 2017-10-08 Impact factor: 3.835
Authors: Ragna S Boerma; T Sonia Boender; Michael Boele van Hensbroek; Tobias F Rinke de Wit; Kim C E Sigaloff Journal: J Int AIDS Soc Date: 2015-12-02 Impact factor: 5.396